DeepMed Research

Nathan S. Kline Institute for Psychiatric Research

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.rfmh.org

Clinical Trials

Sodium Butyrate For Improving Cognitive Function In Schizophrenia

Phase 2

Withdrawn

Conditions: Schizophrenic Disorders
Cognitive Function

Interventions: Dietary Supplement: Sodium Butyrate
Other: Placebo

First Posted Date: 2016-01-13

Last Posted Date: 2016-08-15

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Registration Number: NCT02654405

Locations: 🇺🇸
Nathan Kline Insitute for Psychiatric Research, Orangeburg,, New York, United States

D-serine and Cognitive Remediation in Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: D-serine

First Posted Date: 2014-06-05

Last Posted Date: 2020-10-08

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 8

Registration Number: NCT02156908

Locations: 🇺🇸
Nathan Kline Institute, Orangeburg, New York, United States

Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic

Not Applicable

Completed

Conditions: Cognition
Cigarette Smoking
Schizophrenia

Interventions: Device: tDCS

First Posted Date: 2014-05-01

Last Posted Date: 2017-08-30

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 33

Registration Number: NCT02128919

Locations: 🇺🇸
Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, United States

N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia

Phase 2

Conditions: Schizoaffective Disorder
Schizophrenia

Interventions: Drug: placebo
Drug: D-serine
Behavioral: Sensory Based remediation paradigm

First Posted Date: 2011-11-18

Last Posted Date: 2012-10-25

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 16

Registration Number: NCT01474395

Locations: 🇺🇸
Nathan Kline Insitute for Psychiatric Research, Orangeburg, New York, United States

Conversion to Antipsychotic Monotherapy

Not Applicable

Terminated

Conditions: Schizoaffective Disorder
Schizophrenia

Interventions: Other: Conversion to Antipsychotic Monotherapy

First Posted Date: 2011-06-08

Last Posted Date: 2017-02-09

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 24

Registration Number: NCT01368458

Metformin for Weight Loss in Schizophrenia

Not Applicable

Terminated

Conditions: Schizophrenia
Obesity

Interventions: Drug: Metformin

First Posted Date: 2010-08-09

Last Posted Date: 2017-09-01

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 12

Registration Number: NCT01177709

Locations: 🇺🇸
Manhatan Psychiatric Center, New York, New York, United States

Clozapine and Olanzapine Treatment of Aggression

Not Applicable

Completed

Conditions: Schizophrenia

Interventions: Drug: Olanzapine
Drug: Clozapine
Drug: Haloperidol

First Posted Date: 2010-05-14

Last Posted Date: 2010-05-14

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 110

Registration Number: NCT01123408

Locations: 🇺🇸
Nathan Kline Institute, Orangeburg, New York, United States

Cognitive Skills Training Using Computer for Patients With Severe Mental Illness

Phase 4

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Behavioral: CRT and Social Cognition
Behavioral: Computerized Cognitive Skill Training

First Posted Date: 2009-12-21

Last Posted Date: 2017-07-21

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 448

Registration Number: NCT01036282

Locations: 🇺🇸
Manhattan Psychiatric Center, New York, New York, United States

D-serine for the Schizophrenia Prodrome

Phase 2

Completed

Conditions: Schizophrenia Prodrome

Interventions: Drug: D-serine
Other: Placebo

First Posted Date: 2009-01-22

Last Posted Date: 2017-08-14

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 44

Registration Number: NCT00826202

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
Zucker Hillside Hospital, Glen Oaks, New York, United States
🇺🇸
New York State Psychiatric Institute, New York, New York, United States

and more 1 locations

Biomarkers in Schizophrenia

Phase 2

Completed

Conditions: Schizoaffective Disorder
Schizophrenia

Interventions: Drug: D Serine
Drug: Placebo

First Posted Date: 2009-01-06

Last Posted Date: 2017-08-02

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 16

Registration Number: NCT00817336

Locations: 🇺🇸
Nathan Kline Institute, Orangeburg, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy